

STUDIENLISTE CCC

Studien offen; Kantonsspital St. Gallen

GASTROINTESTINAL

BAUCHSPEICHELDRÜSE

[NISB793](#)
[Pankreas](#)

A phase II open label randomized study testing NIS793 (with and without spartalizumab) in combination with SoC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

[Daniel.Horber](#)
[@kssg.ch](#)

DARM

[DOSIS RCT](#)

Dose-intensified-image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastasis versus Conventional Therapy: A Randomized Controlled Trial

[Guido.Henke](#)
[@kssg.ch](#)

LEBER

[MSD MK-3475-937](#)

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937).

[David.Semela](#)
[@kssg.ch](#)

[COSMIC 312](#)

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL 84) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

[David.Semela](#)
[@kssg.ch](#)

GYNÄKOLOGIE

VULVA

[Woman](#)
[PRO III](#)

Effectiveness of a multidimensional mobile app intervention "WOMAN-PRO III" to reduce postsurgical symptom induced distress in patients with vulvar neoplasia: A mixed methods project

[Rene.Hornung](#)
[@kssg.ch](#)

HÄMATO-ONKOLOGIE

LEUKÄMIE

[Blincyto](#) An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practice. [Michael. Baumann @kssg.ch](#)

[ELEVATE](#) An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia [Marcus. Schittenhelm @kssg.ch](#)

[VerVe](#) Observational study of the use of venetoclax in patients with chronic lymphocytic leukemia (CLL) under real-life setting in Austria, Germany and Switzerland (Venetoclax Real Value) [Michael. Baumann @kssg.ch](#)

LYMPHOM

[SAKK HD 21](#) Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD. [Felicitas.Hitz @kssg.ch](#)

KUTANES LYMPHOM

[RESMAIN](#) A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy [Antonio.Cozzio @kssg.ch](#)

HAUT

MELANOM

[ENIGMA](#) Open label, non randomized, Phase IB study to characterize safety, tolerability and recommended dose of Tinostamustine (EDO-S101), a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic MelAnoma. [Markus.Joerger @kssg.ch](#)

[IMIT](#) Immunmonitoring of patients before, during and after immunotherapy to predict anti-tumor response in melanoma and non-small cell lung cancer. [Lukas.Flatz @kssg.ch](#)

[SAKK 66/17](#) Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients. [Markus.Joerger@kssg.ch](#)

KUTANES LYMPHOM

[RESMAIN](#) A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy [Antonio.Cozzio@kssg.ch](#)

KOPF und HALS

[Induce-3](#) A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. [Veronika.Nagy@kssg.ch](#)

ORL

HNO

[DOSIS RCT](#) Dose-intensified-Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastasis versus Conventional Therapy: A Randomized Controlled Trial. [Guido.Henke@kssg.ch](#)

[10/16 EORTC](#) Phase III study assessing the “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma. [Sandro.Stöckli@kssg.ch](#)

SARKOME

[E-TRAB](#) Geriatric assessment of elderly “unsuited” patients receiving trabectedin in first line treatment for advanced soft tissue sarcomas (STS). [Christian.Rothermundt@kssg.ch](#)

[SAKK 66/17](#) Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients. [Markus.Joerger@kssg.ch](#)

SENOLOGIE

MAMMA

Adjuvant

[Daiichi Sankyo](#)

A Phase III, multicenter, randomized, open-label, active-controlled trial of DS-8201A, an anti-HER2-antibody drug conjugate (ADC), versus treatment of Physician's choice for HER2low, unresectable and/or metastatic breast cancer subjects.

[Ursula.Hasler-Strub@kssg.ch](#)

[TOUCH IBCSG 55-17](#)

A Phase II open label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer.

[Ursula.Hasler-Strub@kssg.ch](#)

MAMMA

Metastasierend

[DOSIS RCT](#)

Dose-intensified-Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastasis versus Conventional Therapy: A Randomized Controlled Trial.

[Guido.Henke@kssg.ch](#)

THORAX

LUNGE

[ACHILES \(MO40379\)](#)

A randomized phase II study comparing atezolizumab after concurrent chemo-radiotherapy with chemo-radiotherapy alone in limited disease small-cell lung cancer.

[Christina.Appenzeller@kssg.ch](#)

[BMS CA 209-73L](#)

Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs. CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

[Martin.Frueh@kssg.ch](#)

[DOSIS RCT](#)

Dose-intensified-Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastasis versus Conventional Therapy: A Randomized Controlled Trial.

[Guido.Henke@kssg.ch](#)

[EORTC 1702-LCG-ROG](#)

Targeted therapy with or without dose-intensified radiotherapy in oligoprogressive disease (OPD) in oncogene Addicted Lung Tumors.

[Markus.Glatzer@kssg.ch](#)

[ETOP 13-018-meso](#)

A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma.

[Martin.Frueh@kssg.ch](#)

| | | |
|---|---|--|
| <u>ETOP 15-19 ABC Lung</u> | A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed in EGFR mutant non-small cell lung carcinoma with acquired resistance | <u>Martin.Frueh @kssg.ch</u> |
| <u>GO41717</u> | A Phase III, randomized, double-blinded, placebo-controlled study of Tiragolumab, an Anti-Tigit Antibody, in combination with Atezolizumab compared with placebo in combination with Atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1 selected Non-Small Cell Lung Cancer. | <u>Markus.Joerger @kssg.ch</u> |
| <u>KeyImPaCT MK3475-495</u> | A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer. | <u>Martin.Frueh @kssg.ch</u> |
| <u>SAKK 16/18</u> | Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III(N2) Non-small Cell Lung Cancer (NSCLC). A multicenter phase II trial. | <u>Martin.Frueh @kssg.ch</u> |
| <u>SAKK 19/17</u> | First line durvalumab in patients with PD-L1 positive, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial. | <u>Martin.Frueh @kssg.ch</u> |
| St.Gallen Lungen Biobank | Das Lungenzentrum des Kantonsspitals St.Gallen führt seit 2011 eine Biobank, in der biologische Proben von Lungenkrebspatienten systematisch konserviert werden. Dabei handelt es sich um ein interdisziplinäres Projekt der Kliniken für Pneumologie / Schlaf-medicin, Thoraxchirurgie, Pathologie und Medizinische Onkologie und Hämatologie. | <u>Florent.Baty @kssg.ch</u> |

UROLOGIE

HODEN

| | | |
|-----------------------------------|---|--|
| <u>SAG TCCS</u> | Prospektive Datenerhebung bei Patienten mit Hodenkrebs. | <u>Christian. Rothermundt @kssg.ch</u> |
| <u>SAKK 01/18</u> | Reduced intensity radio-chemotherapy for satge IIA/B seminoma. A multicenter, open label phase II trial with 2 cohorts. | <u>PaulMartin. Putora @kssg.ch</u> |

NIERE

| | | |
|--|---|--|
| <u>Checkmate 914</u> | A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs. Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse | <u>Christian. Rothermundt @kssg.ch</u> |
| <u>Ipsen F-FR-60000- 023</u> | A phase II, multicentre, Open label study of CABOZANTINIB as 2nd line treatment in subjects with unresectable, locally advanced or metastatic renal cell carcinoma with a clear-cell component who progressed after 1st line treatment with checkpoint inhibitors | <u>Christian. Rothermundt @kssg.ch</u> |
| <u>SAKK 07/17</u> | Nivolumab in combination with Ipilimumab in patients with metastatic renal cell carcinoma: A multicentre single-arm phase II trial. | <u>Christian. Rothermundt @kssg.ch</u> |

PROSTATA

| | | |
|--|---|--|
| <u>DOSIS RCT</u> | Dose-intensified-Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastasis versus Conventional Therapy: A Randomized Controlled Trial. | <u>Guido.Henke @kssg.ch</u> |
| <u>MK-3475-991</u> | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | <u>Aurelius.Omlin @kssg.ch</u> |
| <u>PAE in advanced prostate cancer</u> | Prostatic Artery Embolization in Advanced Prostate Cancer. A pilot study. | <u>Dominik.Abt @kssg.ch</u> |
| <u>SAKK 08/14 IMPROVE</u> | Investigation of Metformin in patients with castration resistant Prostate Cancer in combination with Enzalutamide vs. Enzalutamide alone. | <u>Christian. Rothermundt @kssg.ch</u> |
| <u>SAKK 08/15 PROMET</u> | Multicenter, Randomized Phase II trial of Salvage Radiotherapy "+/-" Metformin for Patients with Prostate Cancer after Prostatectomy. | <u>PaulMartin. Putora @kssg.ch</u> |
| <u>STAMPEDE</u> | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial. | <u>Daniel.Engeler @kssg.ch</u> |
| <u>STORM: PEACE V</u> | A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases. | <u>PaulMartin. Putora @kssg.ch</u> |

[Prostate
Cancer
Biobank](#)

Prospective Cohort Study With Collection of Clinical Data, Serum and Plasma of Patients With Prostate Disease.

[Daniel.Engeler
@kssg.ch](#)

ZNS

GEHIRN

[RESURGE](#)

Randomized Controlled Comparative Phase II Trial on Surgery for Glioblastoma Recurrence.

[Evangelos.
Kogias
@kssg.ch](#)

PHASE I-STUDIEN

[ADORE
CINC 424](#)

A randomized, open-label, phase I/II open platform study evaluating safety and efficacy of novel ruxolitinib combinations in myelofibrosis patients.

[Thomas.
Lehmann
@kssg.ch](#)

[Bayer 18594](#)

An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY1895344 in patients with advanced solid tumors and lymphomas.

[Markus.Joerger
@kssg.ch](#)

[CB-103
Cellestia](#)

A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway.

[Dagmar.Hess
@kssg.ch](#)

[EDO
Phase I
EXPANSION](#)

A Phase I Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies.

[Christoph.
Driessen
@kssg.ch](#)

[NIR178](#)

A Phase II, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma.

[Markus.Joerger
@kssg.ch](#)

[SAKK 65/16](#)

TLD-1, a novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors; a multicenter open-label single-arm phase I trial.

[Dagmar.Hess
@kssg.ch](#)
